Titan Biotech Ltd, a small-cap specialty chemical company, has declared that the Board of Directors, at its meeting held on Saturday, 29th November, 2025 has announced sub-division/split of equity shares of the company, such that 1 equity share having a face value of Rs. 10/- each, fully paid-up, be sub-divided into 5 equity shares having a face value of Rs. 2/- each, fully paid-up subject to the approval of the Members of the company.
For the above-discussed 5:1 stock split, the record date shall be intimated after seeking approval of the Members of the company, according to Titan Biotech.
The goal of Titan Biotech Limited’s 5:1 stock split is to increase liquidity and make the stock more accessible to regular investors by lowering the face value of each equity share from Rs 10 to Rs 2. As per the disclosure, the company’s authorised share capital will increase from 1,00,00,000 equity shares of Rs 10 each to 5,00,00,000 equity shares of Rs 2 each, while the issued and paid-up share capital will rise from 82,63,700 shares to 4,13,18,500 shares after the split, maintaining the same overall capital value.
The rationale behind the stock split is “to enhance the liquidity of the company’s equity shares and to encourage participation of retail investors by making equity shares of the Company more affordable,” said Titan Biotech in a stock exchange filing.
The company has indicated that the share split process is expected to be completed within two months, subject to shareholders’ approval.
In terms of financials, the firm generated revenue from operations of Rs 54.35 crore in the September 2025 quarter, increasing 36.26% from Rs 39.89 crore in the September 2024 quarter. Its net profit amounted to Rs. 6.86 crore in the quarter ended in September 2025, rising 37.15% from Rs. 5.00 crore in the quarter ended in September 2024. EBITDA stood at Rs. 10.65 crore in Q2FY26, increasing 31.81% from Rs. 8.08 crore in Q2FY25.
Titan Biotech Target Price
“Titan Biotech stock price is bearish on the Daily charts with strong resistance at 1074. A Daily close below support of 930 could lead to a target of 866 in the near term,” commented A R Ramachandran, Independent SEBI registered Research Analyst, Tips2trades.